“Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues”, J Infect Dis, vol. 202, pp. 1648-1658, 2010.
, “Determination of the 50% Human Infectious Dose for Norwalk Virus”, J Infect Dis, vol. 209, pp. 1016-1022, 2014.
, “Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults”, J Infect Dis, vol. jiu497 [pi, 2014.
, “Norovirus Vaccine Against Experimental Human Norwalk Virus Illness”, N Engl J Med, vol. 365, pp. 2178-2187, 2011.
, “A Novel Intramuscular Bivalent Norovirus Virus-Like Particle Vaccine Candidate-Reactogenicity, Safety, and Immunogenicity in a Phase 1 Trial in Healthy Adults”, J Infect Dis, vol. pii: jiu33, 2014.
, “Safety and Immunogenicity of Tetanus Diphtheria and Acellular Pertussis (Tdap) Immunization During Pregnancy in Mothers and Infants: A Randomized Clinical Trial”, JAMA, vol. 311, pp. 1760-1769, 2014.
, “Safety and Immunological Outcomes Following Human Inoculation with Nontypeable Haemophilus Influenzae”, J Infect Dis, vol. 208, pp. 728-738, 2013.
, “Seroprevalence and Risk Factors for Cytomegalovirus Infections in Adolescent Females”, J Ped Infec Dis, vol. 2, pp. 7-14, 2013.
, “Seroprevalence of Cytomegalovirus (CMV) and Risk Factors for Infection in Adolescent Males”, Clinical Infectious Diseases, vol. 51, pp. e76-e81, 2010.
,